Physician profile
Pushparanee Babusukumar
NPI 1003919697
$1,536.37
in general payments reported to CMS, 2019-2025
19 companies · $499 in 2025
The $499 reported for 2025 was more than what a typical Psychiatry provider received nationally (typical 2025 total: $176).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $417 · 2020: $77.68 · 2023: $58.27 · 2024: $484 · 2025: $499.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,041.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,041.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Neurocrine Biosciences, INC. | $188.71 | 2019-2025 | Ingrezza |
| Janssen Pharmaceuticals, INC | $164.26 | 2019-2025 | Invega Sustenna, Spravato, Invega Trinza |
| Teva Pharmaceuticals USA, INC. | $150.10 | 2020-2025 | Uzedy, Austedo Xr, Austedo Xr |
| Otsuka America Pharmaceutical, INC. | $143.09 | 2019-2025 | Rexulti, Abilify Asimtufii, Abilify Maintena |
| Alkermes, INC. | $124.43 | 2019-2025 | Aristada, Lybalvi |
| Lundbeck LLC | $120.82 | 2019-2025 | Abilify Asimtufii, Abilify Maintena, Rexulti |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $109.28 | 2023-2025 | Caplyta |
| Allergan, INC. | $92.56 | 2019 | |
| Abbvie INC. | $84.94 | 2024-2025 | |
| Sunovion Pharmaceuticals INC. | $74.44 | 2019-2020 | |
| Vanda Pharmaceuticals INC. | $65.21 | 2024-2025 | Fanapt |
| Axsome Therapeutics, INC. | $57.21 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $45.24 | 2020-2024 | Trintellix |
| Shire North American Group INC | $33.48 | 2019 | |
| Avanir Pharmaceuticals, INC. | $21.28 | 2019 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Idorsia Pharmaceuticals US INC | $20.57 | 2024 | Quviviq |
| E.R. Squibb & Sons, L.L.C. | $15.17 | 2025 | Cobenfy |
| Bausch Health US, LLC | $13.34 | 2020 | |
| Ironshore Pharmaceuticals INC. | $12.24 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Pushparanee Babusukumar listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.